Compare PAVM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVM | PPBT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 6.5M |
| IPO Year | 2016 | N/A |
| Metric | PAVM | PPBT |
|---|---|---|
| Price | $0.29 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 272.8K | ★ 731.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.53 |
| 52 Week High | $0.90 | $5.20 |
| Indicator | PAVM | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 42.65 |
| Support Level | $0.27 | $0.67 |
| Resistance Level | $0.31 | $0.87 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 17.97 | 17.54 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.